COMMUNIQUÉS West-GlobeNewswire

INmune Bio Inc. Announces 2025 Results and Provides Business Update
30/03/2026
Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results
30/03/2026
NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to [...]
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
30/03/2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first [...]
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
30/03/2026
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, [...]
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
30/03/2026
WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced [...]
Inventiva reports 2025 full year results and provides a business update
30/03/2026
Revenues of €4.5 million for the full year of 2025 Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits 1 as at December 31, 2025 Completed a U.S. registered public offering for gross [...]
Children’s National Hospital announces new pain management center to help children and their families reclaim their lives from chronic pain
30/03/2026
Supported by an $8.895 million investment, new center will deliver comprehensive, multidisciplinary care for children and adolescents experiencing acute and chronic pain Washington, DC, March 30, 2026 (GLOBE NEWSWIRE [...]
IBA – ACQUISITION OF OWN SHARES
30/03/2026
Louvain-la-Neuve, Belgium, March 30 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
IBA – ACQUISITION D’ACTIONS PROPRES
30/03/2026
Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
30/03/2026
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an [...]
Terra Pharm Medical Marijuana Organization Opens Cultivation Facility and Dispensaries in Pennsylvania
30/03/2026
Pennsylvania’s newest medical marijuana organization partners with Duquesne University Nasuti College of Osteopathic Medicine on evidence-based research. PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Terra Pharm, [...]
Major Shareholder Announcement
30/03/2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis [...]
Grâce à des avancées significatives dans le financement de son projet industriel en France, Carbios confirme son objectif de construction de l’usine de Longlaville.
30/03/2026
Carbios confirme son objectif concernant le projet de construction de l’usine de Longlaville, dans le cadre d’un financement de projet, avec pour objectif un démarrage de production à horizon S1 2028. Carbios dispose d’ [...]
Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant
30/03/2026
Carbios confirms its objective for the Longlaville plant construction project, within a project financing framework and a target of starting production by H1 2028. Carbios has a solid cash position, with around €60 [...]
Novo Nordisk A/S - share repurchase programme
30/03/2026
Bagsværd, Denmark, 30 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Anavex Life Sciences Provides Comprehensive Regulatory Update
30/03/2026
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective to discuss [...]
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
30/03/2026
Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung [...]
Elevar Therapeutics Announces FDA Acceptance for Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment
30/03/2026
With Priority Review designation, FDA set a Sept. 27 PDUFA date for approval decision Lirafugratinib achieved a 46.5% ORR, in CCA patients with FGFR2 fusion and rearrangement Fort Lee, N.J., March 30, 2026 (GLOBE [...]
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
30/03/2026
CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]

Pages